US Stock Insider Trading | Recursion disclosed three insider transactions on February 6

2026-03-07 01:02:41

On February 6, 2026, Recursion (RXRX) disclosed three insider trading transactions. Director Blake Borgeson sold 220,000 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Director	Blake Borgeson	February 3, 2026	Sell	220,000	4.20	924,000
February 6, 2026	Director	Christopher Gibson	February 4, 2026	Sell	40,000	4.12	164,800
February 6, 2026	Director	Christopher Gibson	February 6, 2026	Sell	10,400	3.56	36,944
January 22, 2026	Director	Christopher Gibson	January 20, 2026	Sell	40,000	4.47	178,800
January 8, 2026	Director	Blake Borgeson	January 6, 2026	Sell	220,000	4.36	959,200
January 7, 2026	Director	Christopher Gibson	January 5, 2026	Sell	40,000	4.25	170,000
December 30, 2025	Executive	Ben R. Taylor	December 29, 2025	Sell	21,400	4.18	89,572
December 29, 2025	Director	Najat Khan	December 22, 2025	Sell	124,400	4.41	548,004
December 19, 2025	Director	Christopher Gibson	December 19, 2025	Sell	40,000	4.50	180,000
December 17, 2025	Executive	Ben R. Taylor	December 15, 2025	Sell	7,057	4.33	30,558

[Company Profile]

Recursion Pharmaceuticals, Inc. was originally founded on November 4, 2013, and registered in Delaware. The company is a leading clinical-stage TechBio firm that decodes biology to industrialize drug discovery. The core mission is based on the Recursive Operating System (OS), a platform built across multiple technologies that enables the company to map and navigate trillions of biologically, chemically, and patient-centric relationships within over 50 PB of proprietary data. The company frames this integration of physical and digital components as an iterative cycle, where scaled “wet lab” biological, chemical, and patient-centered experimental data are organized by “dry lab” computational tools to identify, validate, and translate therapeutic insights.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes